`
`Case 1:18-cv-01363-CFC Document118 Page1of 3 PagelD #: 14065Filed 04/29/19
`
`
`
`Frederick L. Cottrell, III
`Director
`
`302-651-7509
`cottrell@rlf.com
`
`April 22, 2019
`
`BY CM/ECF AND HAND DELIVERY
`The Honorable Colm F, Connolly
`United States District Court
`District of Delaware
`844 North King Street
`Wilmington, DE 19801-3555
`
`RICHARDS
`[AYTON Se
`f]NGER
`
`REDACTED PUBLIC VERSION
`
`Re: Genentech, Inc. v. Samsung Bioepis Co., C.A. No. 18-1363-CFC
`
`Dear Judge Connolly:
`
`I write jointly on behalf of Plaintiffs Genentech, Inc. and City of Hope and Defendant
`Samsung Bioepis Co., Ltd. in advance of the claim construction hearing that is scheduled in this
`case for April 24, 2019 to address the claim construction U.S. Patent Nos. 6,627,196 (“the °196
`patent”), 7,371,379 (“the °379 patent”), 7,485,704 (“the ’704 patent”), and 10,160,811 (“the ’811
`patent’).
`
`With respect to the ’704 patent, the parties stipulate and agree for purposesof this case to
`the construction of (i) “about” as “no more than + | °C”; and (ii) “performing subsequent
`purification of compositions comprising said protein by Protein A chromatography at a
`[temperature range]” as “performing subsequent purification of compositions comprising said
`protein by Protein A chromatography, wherein the composition being purified is at a [temperature
`range|.”
`
`With respect to the ’196, ?379, and ’811 patents, Samsung Bioepis is currently approved to
`marketits trastuzumab biosimilar productforall indications in the Herceptin® label. Accordingly,
`for purposesofthis case, the parties are willing to stipulate to the construction of“an initial dose”
`as “the first dose of the claimed antibody given to the patient as part of a treatment regimen”
`
`because Plaintiffs believe there is no ripe dispute as to this claim term.
`
`In view of the parties’ agreement with respect to these claim terms in view of the current
`posture of the case, there is no issue of claim construction for the Court to decide with respect to
`the ’704 patent or the *196, °379, and ’811 patents in this case.
`
`
`
`Case 1:18-cv-01363-CFC Document118
`
`Filed 04/29/19
`
`Page 2 of 3 PagelD #: 14066
`
`The Honorable Colm F. Connolly
`April 22, 2019
`Page 2 of 2
`
`The parties are submitting herewith a stipulation and proposed order memorializing their
`agreement with respect to these claim terms. Please let us know if Your Honor has any questions
`or concerns regarding the foregoing. Counsel are available at the Court’s convenience in
`connection with this matter.
`
`Respectfully,
`
`/s/ Frederick £. Cottrell, IT
`
`Frederick L. Cottrell, UIE (#2555)
`
`FLC,IHafg
`ce:
`All Counsel of Record (via CM/ECF and email)
`
`
`
`
`
`
`
`
`
`Case 1:18-cv-01363-CFC Document118_Filed 04/29/19 Page 3 of 3 PagelD #: 14067
`
`
`
`CERTIFICATEOFSERVICE
`
`Thereby certify that on April 22, 2019, true and correct copies ofthe foregoing document were caused
`
`be served on the following counsel in the mannerindicated:
`
`VIA ELECTRONIC MAIL
`David Moore
`Bindu Ann Palapura
`POTTER ANDERSON CORROON LLP
`1313 North Market Street, 6th Floor
`Wilmington, Delaware 19801
`dmoore@potteranderson.com
`bpalapura@potteranderson.com
`
`VIA ELECTRONIC MAIL
`Amit Thakore
`Dimitrios T. Drivas
`Holly Tao
`Scott T. Weingaertner
`John P. Padro
`WHITE & CASE LLP
`1221 Avenue of the Americas
`New York, New York 10020-1095
`athakore@whitecase.com
`ddrivas@whitecase.com
`holly.tao@whitecase.com
`sweingaertner@whitecase.com
`jpadro@whitecase.com
`
`/s/ Jason J. Rawnsley
`Jason J. Rawnsley 5379)
`rawnsley@rlf.com
`
`
`
`